Inclusion Criteria:

• Male or female between 18 and 65 years of age inclusive
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy
• Child-bearing potential and agrees to use one of the contraception methods
• Body weight ≥ 50 kg and body mass index (BMI) within the range 18.5 – 30 kg/m2 (inclusive)
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions
• Single QT duration corrected for heart rate by Bazett’s formula (QTcB) < 450 msec.


Exclusion Criteria:

• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities
• A positive pre-study drug/alcohol screen
• A positive test for HIV antibody
• History of regular alcohol consumption within 6 months of the study
• The subject has participated in a clinical trial and has received an investigational product within the 3 months
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements
• History of sensitivity to any of the study medications, or erythromycin, any macrolide or ketolide antibiotic
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
• The subject has donated blood in the 3 months prior to the study
• Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing
• Lactating females
• Unwillingness or inability to follow the procedures outlined in the protocol
• Subject is mentally or legally incapacitated

• United Kingdom (click to view all sites in United Kingdom)
• GSK Investigational Site
  London, NW10 7EW; Completed;
  Contact: Steve J Warrington, Principal Investigator, .